Abstract 147P
Background
In resectable esophageal squamous cell carcinoma (ESCC), there is limited evidence of the efficacy of serplulimab in combination with chemotherapy followed by minimally invasive esophagectomy. Therefore, we aimed to observe and evaluate its efficacy and safety in locally advanced ESCC.
Methods
Patients aged 18-75 years and classified as stage II-IVA according to the 8th edition of the American Joint Committee on Cancer (AJCC) staging manual, who were histologically or cytologically diagnosed with ESCC, were deemed eligible to participate in this trial. Patients received 3 cycles of neoadjuvant therapy with serplulimab (4.5mg/kg intravenously on day 1), carboplatin (AUC=5 intravenously on day 1), albumin paclitaxel (260 mg/m2 intravenously on day 1); each cycle was repeated every 21 days. Surgery occurred 4-6 weeks after the last neoadjuvant treatment cycle. The primary outcome was the pathological complete response (PCR) rate of the tumour and lymph nodes. This prospective, single-arm, phase 2 trial was conducted at the Second Affiliated Hospital of Zhejiang University in China.
Results
A total of 48 patients were enrolled in this study, with no observed disease progression during the neoadjuvant treatment phase. The disease control rate and objective response rate were 100.0% and 68.8%, respectively. Most of the adverse events were grade 1-2, 2 (4.2%) patients experienced grade 3 adverse events. Three patients refused to receive surgical treatment and declined to participate in the study. Consequently, 45 patients received minimally invasive esophagectomy. All 45 patients achieved R0 resection, with 14 patients (31.1%) attaining a PCR for both the tumour and lymph nodes.
Conclusions
The administration of serplulimab in conjunction with chemotherapy in the neoadjuvant setting for locally advanced ESCC has demonstrated promising antitumor activity and an acceptable safety profile in this single-arm study. Extended follow-up to assess survival outcomes and a phase 3 randomized trial are necessary to further evaluate the efficacy and safety of the proposed treatment regimen.
Clinical trial identification
NCT05659251.
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
43P - Machine learning radiomics based on CT to predict response to lenvatinib plus tislelizumab based therapy for unresectable hepatocellular carcinoma
Presenter: Gang Chen
Session: Poster Display session
Resources:
Abstract
44P - Machine learning-based prediction of survival in patients with metastatic renal cell carcinoma receiving first-line immunotherapy
Presenter: Ahmed Elgebaly
Session: Poster Display session
Resources:
Abstract
45P - Gut microbiome signatures for exploring the correlation between gut microbiome and immune therapy response using machine learning approach
Presenter: Han Li
Session: Poster Display session
Resources:
Abstract
46P - Abnormal gut microbiota may cause PD-1 inhibitor-related cardiotoxicity via suppressing regulatory T cells
Presenter: Zeeshan Afzal
Session: Poster Display session
Resources:
Abstract
47P - Correlation of clinical, genetic and transcriptomic traits with PD-L1 positivity in TNBC patients
Presenter: Anita Semertzidou
Session: Poster Display session
Resources:
Abstract
48P - The A2AR antagonist inupadenant promotes humoral responses in preclinical models
Presenter: Paola Tieppo
Session: Poster Display session
Resources:
Abstract
49P - Highly potent novel armoured IL13Ra2 CAR T cell targeting glioblastoma
Presenter: Maurizio Mangolini
Session: Poster Display session
Resources:
Abstract
50P - Phase I trial of P-MUC1C-ALLO1 allogeneic CAR-T cells in advanced epithelial malignancies
Presenter: David Oh
Session: Poster Display session
Resources:
Abstract
51P - Unlocking CAR-T cell potential: Lipid metabolites in overcoming exhaustion in ovarian cancer
Presenter: Xiangyu Chang
Session: Poster Display session
Resources:
Abstract
52P - Tumor-targeted cytokine release by genetically-engineered myeloid cells rescues CAR-T activity and engages endogenous T cells against high-grade glioma in mouse models
Presenter: Federico Rossari
Session: Poster Display session
Resources:
Abstract